# MicroActive Resveratrol (Polygonum cuspidatum)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/microactive-resveratrol
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-31
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Polygonum cuspidatum extract, Japanese knotweed extract, Fallopia japonica, Reynoutria japonica, Hu Zhang, Itadori, Sustained-release resveratrol, Standardized resveratrol extract, Trans-resveratrol complex

## Overview

MicroActive Resveratrol is a sustained-release form of trans-resveratrol extracted from Polygonum cuspidatum, standardized to over 73.8% trans-resveratrol content. It activates the [longevity](/ingredients/condition/longevity)-associated sirtuin SIRT1 and inhibits NF-κB signaling, positioning it as a potent [antioxidant](/ingredients/condition/antioxidant) and [anti-inflammatory](/ingredients/condition/inflammation) compound.

## Health Benefits

• No clinical evidence available - search results contain no human trials on MicroActive Resveratrol
• Traditional use documented - P. cuspidatum is used in traditional Chinese medicine as a resveratrol source
• High purity extract - standardized to >73.8% trans-resveratrol content
• Contains multiple bioactives - includes trans-resveratrol, polydatin, and emodin compounds
• Sustained-release formulation - branded ingredient designed for extended release (no clinical data on release profile)

## Mechanism of Action

Trans-resveratrol activates SIRT1 (sirtuin-1), a NAD+-dependent deacetylase that regulates gene expression linked to cellular [longevity](/ingredients/condition/longevity), [mitochondrial biogenesis](/ingredients/condition/energy), and inflammation. It also inhibits NF-κB transcription factor activity, reducing downstream production of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s such as TNF-α and IL-6. Additionally, trans-resveratrol scavenges [reactive oxygen species](/ingredients/condition/antioxidant) (ROS) directly and upregulates endogenous antioxidant enzymes including superoxide dismutase (SOD) and catalase.

## Clinical Summary

No published human clinical trials have been conducted specifically on the MicroActive Resveratrol branded form to date, making direct evidence-based claims premature. General resveratrol research includes small randomized controlled trials — typically 20 to 60 participants — examining metabolic, [cardiovascular](/ingredients/condition/heart-health), and [cognitive](/ingredients/condition/cognitive) outcomes, often using doses between 150 mg and 1000 mg daily with mixed results. The MicroActive delivery technology is designed to improve the notoriously poor bioavailability of standard resveratrol (oral bioavailability under 1%), theoretically improving plasma concentration, but this has not been validated in large-scale trials. Until brand-specific clinical data are published, efficacy conclusions should be drawn cautiously from general resveratrol literature.

## Nutritional Profile

MicroActive Resveratrol is a sustained-release, microencapsulated extract derived from Polygonum cuspidatum (Japanese knotweed) root. It is not a macronutrient source and provides negligible calories, protein, fat, carbohydrates, or fiber at typical supplement doses (100–500 mg/day). **Primary bioactive compounds:** • **trans-Resveratrol (3,5,4'-trihydroxystilbene):** Standardized to >73.8% by weight; this is the principal active polyphenolic stilbene. A 250 mg dose delivers approximately 185 mg trans-resveratrol. • **Polydatin (resveratrol-3-O-β-glucoside):** Present as a naturally co-occurring glycosylated form of resveratrol, typically 5–15% of total extract; acts as a prodrug converting to free resveratrol in vivo. • **Emodin (1,3,8-trihydroxy-6-methylanthraquinone):** A minor anthraquinone constituent naturally present in P. cuspidatum, generally <2–5% of extract; possesses independent bioactivity but is not the target compound. **Micronutrients:** Trace amounts of minerals inherent to the plant matrix (negligible at supplement doses). No significant vitamin content. **Bioavailability notes:** Unformulated trans-resveratrol has notoriously poor oral bioavailability (~1–5% as free resveratrol) due to rapid Phase II conjugation (sulfation and glucuronidation) in the intestinal epithelium and liver. The MicroActive sustained-release matrix uses a proprietary microencapsulation technology (typically involving starch or lipid carriers) designed to provide gradual release over approximately 12 hours, which may improve the area-under-the-curve (AUC) for plasma resveratrol compared to immediate-release forms. Manufacturer-sponsored pharmacokinetic data suggest 2× greater bioavailability and more consistent plasma levels versus standard resveratrol, though independent peer-reviewed human PK validation is limited. Primary circulating metabolites include resveratrol-3-O-sulfate and resveratrol-3-O-glucuronide, which may retain partial biological activity. Co-administration with dietary fat or quercetin may modestly inhibit conjugation and enhance free resveratrol absorption.

## Dosage & Preparation

No clinically studied dosage ranges are available in the search results. No information on standardized forms, extract potencies, or recommended doses was found. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Resveratrol is generally considered safe at doses up to 1000 mg per day in short-term studies, with mild gastrointestinal side effects such as nausea and diarrhea reported at higher doses. It inhibits CYP3A4 and CYP2C9 liver enzymes, which can increase plasma levels of drugs including warfarin, statins, and certain calcium channel blockers, raising the risk of adverse effects. Resveratrol has estrogenic activity via binding to estrogen receptors ERα and ERβ, making it potentially contraindicated for individuals with hormone-sensitive conditions such as estrogen receptor-positive breast cancer. Pregnant and breastfeeding women should avoid supplementation due to insufficient safety data.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses were found in the search results for MicroActive Resveratrol or resveratrol from P. cuspidatum. No PubMed PMIDs are available as no clinical studies were identified.

## Historical & Cultural Context

Polygonum cuspidatum is a well-known traditional Chinese medicine, historically used as a source of resveratrol. Specific traditional indications and duration of use are not detailed in the available research.

## Synergistic Combinations

Insufficient research data to recommend synergistic ingredients

## Frequently Asked Questions

### What makes MicroActive Resveratrol different from regular resveratrol?

MicroActive Resveratrol uses a sustained-release microencapsulation technology designed to overcome the extremely poor oral bioavailability of standard trans-resveratrol, which is typically absorbed at less than 1% due to rapid metabolism and efflux. The MicroActive delivery system is intended to extend the release window across several hours, potentially maintaining more consistent plasma concentrations. However, no published peer-reviewed human pharmacokinetic studies have confirmed superior bioavailability for this specific branded form.

### What is the source of MicroActive Resveratrol?

MicroActive Resveratrol is derived from Polygonum cuspidatum, also called Japanese knotweed, which is one of the richest natural plant sources of trans-resveratrol. The extract is standardized to a minimum of 73.8% trans-resveratrol content, ensuring consistent and high-purity dosing. Polygonum cuspidatum root has been used in traditional Chinese medicine for centuries under the name Hu Zhang, historically for cardiovascular and inflammatory conditions.

### How does resveratrol activate SIRT1?

Trans-resveratrol acts as an allosteric activator of SIRT1 by binding to its N-terminal domain, lowering the Michaelis constant (Km) for acetylated substrate peptides and increasing deacetylase activity. Activated SIRT1 deacetylates downstream targets including PGC-1α, which promotes mitochondrial biogenesis, and p53, which modulates apoptosis and DNA repair. This pathway is one of the proposed mechanisms linking resveratrol to caloric-restriction-mimicking and longevity-associated effects observed in preclinical models.

### Can MicroActive Resveratrol interact with blood thinners like warfarin?

Yes, resveratrol inhibits CYP2C9, the primary liver enzyme responsible for metabolizing warfarin, which can significantly elevate warfarin plasma levels and increase bleeding risk. This interaction has been demonstrated in in vitro enzyme studies and flagged in pharmacokinetic reviews, though large-scale human interaction trials are limited. Anyone taking warfarin, aspirin, or other anticoagulant or antiplatelet medications should consult a healthcare provider before using any resveratrol supplement.

### What dose of resveratrol is typically used in research studies?

Human clinical trials on resveratrol have used a wide range of doses, most commonly between 150 mg and 1000 mg of trans-resveratrol per day, with some metabolic and cardiovascular studies using doses as high as 2000 mg daily. A frequently cited threshold for activating SIRT1 in vivo is approximately 150–500 mg per day, though optimal dosing remains debated due to bioavailability variability. Because MicroActive Resveratrol uses a sustained-release format, effective dosing may differ from immediate-release forms, but no brand-specific dose-response studies are currently published.

### Is MicroActive Resveratrol safe during pregnancy or while breastfeeding?

There is insufficient clinical evidence on the safety of MicroActive Resveratrol during pregnancy or lactation. As with most supplements, it is advisable to consult with a healthcare provider before use during these periods. Traditional use of Polygonum cuspidatum does not establish safety in pregnant or nursing women.

### How does the sustained-release form of MicroActive Resveratrol affect absorption compared to standard resveratrol?

The sustained-release technology in MicroActive Resveratrol is designed to extend absorption over time, potentially improving bioavailability and maintaining steady resveratrol levels longer than immediate-release forms. This formulation may reduce the peak-and-trough effect seen with standard resveratrol extracts. However, direct comparative human studies on this specific sustained-release technology are limited.

### Does MicroActive Resveratrol contain other bioactive compounds besides trans-resveratrol?

Yes, MicroActive Resveratrol from Polygonum cuspidatum contains multiple bioactive compounds including polydatin (a resveratrol glycoside) and emodin, in addition to its standardized trans-resveratrol content of over 73.8%. These additional compounds may contribute synergistic effects, though research specifically evaluating their combined activity in this formulation is limited.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*